Vectura links with Novartis for inhaled asthma/COPD generic

05:42 EDT 29 Jun 2017 | PharmaTimes

British drugmaker Vectura has signed an exclusive deal with Novartis unit Sandoz to develop a generic version of an existing major inhaled combination therapy for asthma and COPD in the US.

Original Article: Vectura links with Novartis for inhaled asthma/COPD generic


More From BioPortfolio on "Vectura links with Novartis for inhaled asthma/COPD generic"

Quick Search


Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

The term allergy is used to describe a response, within the body, to a substance, which is not necessarily harmful in itself, but results in an immune response and a reaction that causes symptoms and disease in a predisposed person, which in turn can cau...